UK Biobank is a not-for-profit organisation dedicated to advancing global health research. We aim to keep access to our database as affordable as possible and only charge our researchers to cover the costs of handling access applications. Learn more about costs.
All researchers are given £40 of credit when they join the UKB-RAP to contribute to compute and storage costs. This credit gives you a chance to learn how to use the platform and set up your workspace, and for some researchers this credit will cover a substantial part of their total analysis costs. That is because we provide and store a copy of the core 30 petabytes of data, therefore you only need to pay for your compute and storage costs on additional data. The UKB-RAP offers you many different choices of the setup of the virtual computer, so that you can tailor for speed and cost, including on-demand and spot instances (which run on unused virtual compute power).
To make our data as accessible as possible, we also offer financial support through several funding programmes.
| Funding programme |
Who can apply? |
What it covers? | How to apply | Funded by… |
|---|---|---|---|---|
| Student applicants | Students or their supervisors | Reduced access fee of £500 (+VAT) for data-only requests | Register with UK Biobank and select the student tier option on the application form. | |
| Global Researcher Access Fund | Researchers from eligible low and middle income countries | Full coverage of application costs | Register for access with UK Biobank. Funding will be applied automatically. | AstraZeneca Bristol Myers Squibb GSK Johnson & Johnson Regeneron |
| Platform Credits Programme | Early-career researchers or those from lower income countries | AWS credits for UKB-RAP: £1000 for set-up, additional funding available | Apply via a Microsoft form | Amazon Web Services (AWS) |
| UKB-RAP Transition Credits Programme | Any researcher not eligible for other funding | £1000 per project for UKB-RAP costs, with additional funding available | Apply via a Microsoft from | Wellcome |
Related to
Comments
0 comments
Article is closed for comments.